Is Lilly planning two brands for tirzepatide? CFO discusses diabetes and obesity possibilities
Eli Lilly is addressing the possibility of two brand names for tirzepatide — again. The drug — which is already approved to treat type 2 diabetes as Mounjaro — could be getting a different brand name when, as anticipated, it gets approved for an obesity indication.
That’s a definite maybe or maybe not, in light of CFO Anat Ashkenazi’s remarks at the Morgan Stanley healthcare conference on Tuesday.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 159,000+ biopharma pros reading Endpoints daily — and it's free.